

Supplementary Appendix

This appendix has been provided by the authors to give readers additional information about their work.

Supplement to: Karapetis CS, Khambata-Ford S, Jonker DJ, et al. *K-ras* mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med* 2008;359:1757-65.

In addition to the authors, the following committee members, site investigators, data managers, and key trial staff participated in the CO.17 study from the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). **NCIC CTG investigators in Canada:** Dr. H. Bliss Murphy Cancer Centre, St. John's, NB — J. Siddiqui; QEII Health Sciences Center, Halifax, NS — B. Colwell; Atlantic Health Sciences Corporation, St. John's, NB — M. Burnell; Moncton Hospital, Moncton, NB — S. Rubin; Hôpital du Sacré-Coeur de Montréal, Montreal — R. Whitton; Centre Hospitalier de l'Université de Montréal—Hôpital Notre-Dame, Montreal — D. Charpentier; Hôpital Charles LeMoine, Greenfield Park, QC — B. Samson; Cancer Centre of Southeastern Ontario, Kingston — A. Tomiak; Lakeridge Health, Oshawa — R. Wierzbicki; Quinte Healthcare Corporation, Belleville, ON — R. Levesque; Niagara Health System, Ontario — B. Findlay; Toronto-Sunnybrook Regional Cancer Centre, Toronto — S. Berry; Toronto East General Hospital, Toronto — J. Meharchand; St. Joseph's Health Centre, Toronto — J. Blondal; Mount Sinai Hospital, Toronto — R. Burkes; St. Michael's Hospital, Toronto — R. Haq; Grand River Regional Cancer Centre, Kitchener, ON — G. Knight; London Regional Cancer Program, Ontario — I. Kerr; Windsor Regional Cancer Centre, Ontario — J. Mathews; Thunder Bay Regional Health Science Centre, North Bay, ON — D. Dueck; St. Boniface General Hospital, Winnipeg — M. Krahn; Allan Blair Cancer Centre, Regina, SK — S. Yadav; Cross Cancer Institute, Edmonton, AB — S. Koski; BC Cancer Agency—Vancouver Cancer Centre, Vancouver, BC — H. Kennecke; BC Cancer Agency—Cancer Centre for the Southern Interior, Kelowna, BC — M. Taylor; BC Cancer Agency—Vancouver Island Cancer Centre, Victoria, BC — H. Anderson; BC Cancer Agency—Fraser Valley Cancer Centre, Surrey, BC — U. Lee. **NCIC CTG central office staff, Kingston, ON:** N. Magoski, S. Virk, Y. Markovich, L. Boudreau, S. Hunt, A. Lewis, D. Nomikos, J. Ottaway, A. Hung, A. Sargeant, V. Classen, J. Baran, L. Pho, A. Garrah, L. Zhu. **Australasian Gastro-Intestinal Trials Group (AGITG) investigators in Australia:** Newcastle Mater Misericordiae Hospital, New South Wales — S. Ackland; Port Macquarie Base Hospital, New South Wales — S. Begbie; St. Vincent's Hospital, Victoria — I. Burns; Launceston General Hospital, Tasmania — I. Byard; Fremantle Hospital, Western Australia — P. Claringbold; Royal Melbourne Hospital, Victoria — P. Gibbs; Prince of Wales Hospital, New South Wales — D. Goldstein; Peter MacCallum Cancer Institute, Victoria — M. Jefford; St. George Hospital, New South Wales — M. Links; Royal Hobart Hospital, Tasmania — R. Lowenthal; Brisbane Adult Mater, Queensland — P. Mainwaring; Royal North Shore Hospital, New South Wales — N. Pavlakis; St. John of God Subiaco, Western Australia — D. Ransom; Nepean Hospital, New South Wales — J. Shannon; Monash Medical Centre, Victoria — A. Strickland; Royal Perth Hospital, Western Australia — J. Trotter; Border Medical Oncology, Victoria — C. Underhill; Sir Charles Gairdner Hospital, Western Australia — G. V. Hazel; Royal Brisbane Hospital, Queensland — D. Wyld; Canberra Hospital, Australian Capital Territory — D. Yip. **AGITG investigators in New Zealand:** Palmerston North Hospital, Palmerston North — R. Isaacs; Christchurch Hospital, Christchurch — M. Jeffrey. **AGITG investigator in Singapore:** National Cancer Centre Singapore — K.F. Foo. **Australian National Health and Medical Research Council (NHMRC) Clinical Trials Centre (AGITG Coordinating Centre) staff:** B. Vachan, A. Pearce, C. Aiken, J. Simard-Lebrun, J. Shoulder, F. Howard. **Bristol-Myers Squibb:** J. Dechamplain, N. Gustafson. **Bristol-Myers Squibb Department of Clinical Biomarkers-Oncology:** D. Malone, C. T. Harbison and P. Teegarden.